http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011161223-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_993a4bfba1bfa31d5a320d9e680769c6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8fc5210ad36dce22387934b7a2fb8d42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f30320139fc84b9ba4298e51d0137f16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef9b262e05836a02d9ef203f65e7131b
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-401
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-401
filingDate 2011-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6cae1c3fb4f67ce11e7555597fbfd6c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b679abb4589009f1be4055d2f22ee68c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aabb78882b1e7c106015679a799aafed
publicationDate 2012-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2011161223-A3
titleOfInvention Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
abstract The invention relates to unitary pharmaceutical oral dosage forms of the active substances lercanidipine and enalapril, as well the pharmacologically acceptable salts thereof, characterized in that the pharmaceutical oral dosage form comprise separate entities of lercanidipine or its pharmaceutically acceptable salts and enalapril or its pharmaceutically acceptable salts.
priorityDate 2010-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4743450-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003180355-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006165789-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006177507-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007190147-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413385
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419502131
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534469
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65866
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9809926
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393239
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413386
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5388962

Total number of triples: 38.